N/A N=282,368 Kaiser Permanente HIV Cohort Study
HIV · AIDS
Primary: Incidence Rate of Malignancies — 513; 3; 238; 20 malignancies per 100,000 person-years — p=<0.001
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=456 Dose-ranging Study of Vilanterol (VI) Inhalation Powder in Children
Asthma
Primary: Change From Baseline in Daily Pre-dose Evening (PM) Peak Expiratory Flow (PEF) From Participant Electronic Daily Diary Averaged Over the 4-week Treatment Period — 215.9…
Phase 4 N=50 Litramine in Weight Maintenance
Weight Maintenance · Overweight · Obese
Primary: Mean Change in Body Weight From Baseline to End of 24 Weeks — 1.62; -0.62 kg
N/A N=46 Arterial Pulse Waveform Contour Analysis for Intraoperative Goal Directed Therapy in Major Abdominal Surgery
Surgical Procedures, Operative
Primary: Length of Postoperative Hospital Stay — 7.5; 5.0 Days
Phase 1 N=30 Pharmacokinetic Study of OPC-1085EL Ophthalmic Solution in Healthy Male Adult Volunteers
Glaucoma · Ocular Hypertension
Primary: Cmax of Carteolol — 0.8558; 0.9984; 1.174; 1.627 ng/mL
N/A N=24 Risk of Narcolepsy Associated With Administration of H1N1 Vaccine
Narcolepsy
Primary: Incidence of Narcolepsy Among Narcoleptic Subjects Exposed or Unexposed to Vaccine — 0.52; 0.11 events per 100,000 person-years
N/A N=292 Asthma in Central Texas Project
Asthma
Primary: Absenteeism, End of Study — 3.83; 4.41; 3.68 percentage of days enrolled
Phase 3 N=161 Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
Anxiety Disorder · Breast Cancer · Depression
Primary: Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage…
Phase 3 N=1,363 Efficacy and Safety of Empagliflozin (BI 10773) / Linagliptin (BI 1356) Fixed Dose Combination in Treatment naïve and Metformin Treated Type 2 Diabetes Patients
Diabetes Mellitus, Type 2
Primary: Change From Baseline in Glycosylated Hemoglobin (HbA1c) for Metformin Background Patients — -1.19; -1.08; -0.62; -0.66 % change from baseline — p=<0.0001
Phase 2 N=80 Zileuton With or Without Celecoxib As Chemopreventive Agents in Smokers
Tobacco Use Disorder
Primary: Median Urinary PGE-M Levels (Pre and Post Treatment) — 12.8; 13.4; 10.5; 3.9 ng/mg creatinine
Phase 2 N=2 Phase 2 Study of Neoadjuvant Vemurafenib in Melanoma Patients With Untreated Brain Metastases
Melanoma
Primary: Activity of Vemurafenib in Untreated Brain Metastases
Phase 3 N=186 Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia
Schizophrenia
Primary: Overall Relapse Rate (in Percent) From Randomization to Exacerbation of Psychotic Symptoms/Impending Relapse. — 19.39; 37.50 relapse rate(percentage of participants)…
Phase 4 N=16 Bioequivalence Study of Temozolomide in Patients With Primary Tumors of the Central Nervous System
Brain Neoplasms, Malignant, Primary
Primary: Cmax — 11.108; 10.575 mcg/mL — p=<0.05
Phase 1 N=16 Computer Vision System for the Blind Veteran
Blindness
Primary: Frequency of Device Failures Per Attempt to Complete a Navigation Course — 4.1; 2 number of device failures per attempt
N/A N=120 Predicting Success With Hearing Aids
Hearing Loss · Presbycusis
Primary: Words-in-noise Test — 12.6 dB S/N